Table 1.
Yale Neoadjuvant Cohort Characteristics
| Characteristic | N | % |
|---|---|---|
| Age (y) | ||
| <50 | 55 | 58.5 |
| ≥50 | 39 | 41.5 |
| Unknown | 0 | 0 |
| Nodal Status | ||
| Positive | 48 | 51.1 |
| Negative | 32 | 34.0 |
| Unknown | 14 | 14.9 |
| Tumor Size (cm) | ||
| <2 | 10 | 10.6 |
| >2 | 83 | 88.3 |
| Unknown | 1 | 1.1 |
| Nuclear Grade | ||
| 1-2 | 48 | 51.1 |
| 3 | 43 | 45.7 |
| Unknown | 3 | 3.2 |
| ER | ||
| Negative | 35 | 37.2 |
| Positive | 57 | 60.7 |
| Unknown | 2 | 2.1 |
| PR | ||
| Negative | 42 | 44.7 |
| Positive | 50 | 53.2 |
| Unknown | 2 | 2.1 |
| HER2 | ||
| Negative | 68 | 72.3 |
| Positive | 25 | 26.6 |
| Unknown | 1 | 1.1 |
| Triple Negative | ||
| Yes | 23 | 24.4 |
| No | 70 | 74.5 |
| Unknown | 1 | 1.1 |
| LPBC | ||
| Yes | 8 | 8.5 |
| No | 84 | 89.4 |
| Unknown | 2 | 2.1 |
| Treatment | ||
| Adriamycin-based | 72 | 76.6 |
| Carboplatin+Taxane+Herceptin | 10 | 10.6 |
| Carboplatin+Abraxane+Avastin | 6 | 6.4 |
| Carboplatin+Abraxane+Herceptin | 3 | 3.2 |
| Carboplatin+Taxol+Etoposide | 1 | 1.1 |
| Cytoxan+Taxotere | 2 | 2.1 |